Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression
A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require...
Saved in:
Published in | Journal of virology Vol. 91; no. 6 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
15.03.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4
+
T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4
+
T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4
+
T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies.
IMPORTANCE
Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4
+
T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells. |
---|---|
AbstractList | A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4+ T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4+ T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies.IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4+ T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells.A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4+ T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4+ T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies.IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4+ T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells. A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 + T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4 + T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4 + T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies. IMPORTANCE Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4 + T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells. A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 T cell counts and control viral replication in the absence of antiretroviral therapy (ART). Systemic cytokine responses may differentiate ECs from subjects with uncontrolled viral replication or from those who require ART to suppress viral replication. We measured 87 cytokines in four groups of women: 73 ECs, 42 with pharmacologically suppressed viremia (ART), 42 with uncontrolled viral replication (noncontrollers [NCs]), and 48 HIV-uninfected (NEG) subjects. Four cytokines were elevated in ECs but not NCs or ART subjects: CCL14, CCL21, CCL27, and XCL1. In addition, median stromal cell-derived factor-1 (SDF-1) levels were 43% higher in ECs than in NCs. The combination of the five cytokines suppressed R5 and X4 virus replication in resting CD4 T cells, and individually SDF-1β, CCL14, and CCL27 suppressed R5 virus replication, while SDF-1β, CCL21, and CCL14 suppressed X4 virus replication. Functional studies revealed that the combination of the five cytokines upregulated CD69 and CCR5 and downregulated CXCR4 and CCR7 on CD4 T cells. The CD69 and CXCR4 effects were driven by SDF-1, while CCL21 downregulated CCR7. The combination of the EC-associated cytokines induced expression of the anti-HIV host restriction factors IFITM1 and IFITM2 and suppressed expression of RNase L and SAMHD1. These results identify a set of cytokines that are elevated in ECs and define their effects on cellular activation, HIV coreceptor expression, and innate restriction factor expression. This cytokine pattern may be a signature characteristic of HIV-1 elite control, potentially important for HIV therapeutic and curative strategies. Approximately 1% of people infected with HIV control virus replication without taking antiviral medications. These subjects, termed elite controllers (ECs), are known to have stronger immune responses targeting HIV than the typical HIV-infected subject, but the exact mechanisms of how their immune responses control infection are not known. In this study, we identified five soluble immune signaling molecules (cytokines) in the blood that were higher in ECs than in subjects with typical chronic HIV infection. We demonstrated that these cytokines can activate CD4 T cells, the target cells for HIV infection. Furthermore, these five EC-associated cytokines could change expression levels of intrinsic resistance factors, or molecules inside the target cell that fight HIV infection. This study is significant in that it identified cytokines elevated in subjects with a good immune response against HIV and defined potential mechanisms as to how these cytokines could induce resistance to the virus in target cells. |
Author | Deng, Xutao Anastos, Kathryn Deeks, Steven G. Crystal, Howard Pillai, Satish K. Young, Mary Kaidarova, Zhanna Abdel-Mohsen, Mohamed Villacres, Maria C. Norris, Philip J. Gibb, Stuart L. Golub, Elizabeth T. Keating, Sheila M. Heitman, John W. Greenblatt, Ruth M. Gange, Stephen J. Jacobs, Evan S. Martin, Jeffrey N. Inglis, Heather C. Zhang, Jinbing Landay, Alan L. Wu, Shiquan |
Author_xml | – sequence: 1 givenname: Evan S. surname: Jacobs fullname: Jacobs, Evan S. organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 2 givenname: Sheila M. surname: Keating fullname: Keating, Sheila M. organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA – sequence: 3 givenname: Mohamed surname: Abdel-Mohsen fullname: Abdel-Mohsen, Mohamed organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Medicine, University of California, San Francisco, San Francisco, California, USA – sequence: 4 givenname: Stuart L. surname: Gibb fullname: Gibb, Stuart L. organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 5 givenname: John W. surname: Heitman fullname: Heitman, John W. organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 6 givenname: Heather C. surname: Inglis fullname: Inglis, Heather C. organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 7 givenname: Jeffrey N. surname: Martin fullname: Martin, Jeffrey N. organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA – sequence: 8 givenname: Jinbing surname: Zhang fullname: Zhang, Jinbing organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 9 givenname: Zhanna surname: Kaidarova fullname: Kaidarova, Zhanna organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 10 givenname: Xutao surname: Deng fullname: Deng, Xutao organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 11 givenname: Shiquan surname: Wu fullname: Wu, Shiquan organization: Blood Systems Research Institute, San Francisco, California, USA – sequence: 12 givenname: Kathryn surname: Anastos fullname: Anastos, Kathryn organization: Albert Einstein College of Medicine, Bronx, New York, USA – sequence: 13 givenname: Howard surname: Crystal fullname: Crystal, Howard organization: SUNY Downstate Medical Center, Brooklyn, New York, USA – sequence: 14 givenname: Maria C. surname: Villacres fullname: Villacres, Maria C. organization: Keck School of Medicine of the University of Southern California, Los Angeles, California, USA – sequence: 15 givenname: Mary surname: Young fullname: Young, Mary organization: Georgetown University Medical Center, Washington, DC, USA – sequence: 16 givenname: Ruth M. surname: Greenblatt fullname: Greenblatt, Ruth M. organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA, Department of Pharmacy, University of California, San Francisco, San Francisco, California, USA, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 17 givenname: Alan L. surname: Landay fullname: Landay, Alan L. organization: Rush University Medical Center, Chicago, Illinois, USA – sequence: 18 givenname: Stephen J. surname: Gange fullname: Gange, Stephen J. organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 19 givenname: Steven G. surname: Deeks fullname: Deeks, Steven G. organization: Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA – sequence: 20 givenname: Elizabeth T. surname: Golub fullname: Golub, Elizabeth T. organization: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 21 givenname: Satish K. surname: Pillai fullname: Pillai, Satish K. organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA – sequence: 22 givenname: Philip J. orcidid: 0000-0003-0526-2088 surname: Norris fullname: Norris, Philip J. organization: Blood Systems Research Institute, San Francisco, California, USA, Department of Laboratory Medicine, University of California, San Francisco, San Francisco, California, USA, Department of Medicine, University of California, San Francisco, San Francisco, California, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28053103$$D View this record in MEDLINE/PubMed |
BookMark | eNptkc1vVCEUxYmpsdPRnWvD0oWvwgPex8bETKZ2mjYmjU7cER7cpygDU-A11r--dDpttHFF4P445957jtCBDx4Qek3JMaV19_5svTomNRG0os0zNKOk7yohKD9AM0LquhKs-3aIjlL6SQjlvOEv0GHdEcEoYTP0Z3GTwy_rIeGlg2uVwWDr8elqXe42A14En2NwDmLCl2AmDbviJWyd1Srb4PHK47UtEFbe4ItgJldk9lTK0eoddaJ0DhEvf28jpFReXqLno3IJXu3POfp6svyyOK3OP39aLT6eV5rxJlejaUvTnPSc1Ya1CgbFlAEG0ALXSvSGMsLU0LQDJd1oGmGaoVeDHtoiMI5sjj7c626nYQNGQxlIObmNdqPijQzKyn8r3v6Q38O1FIzRttjO0du9QAxXUxlJbmzS4JzyEKYkaSdE2zW8pwV987fXo8nDwgvw7h7QMaQUYXxEKJF3ecqSp9zlKWlT8PoJrm3ebb10at3_P90CABylPg |
CitedBy_id | crossref_primary_10_1155_2018_8357109 crossref_primary_10_1371_journal_pone_0306559 crossref_primary_10_3390_ijms24054958 crossref_primary_10_1016_j_ebiom_2017_11_031 crossref_primary_10_1002_JLB_3MR0717_307R crossref_primary_10_3389_fimmu_2021_649465 crossref_primary_10_1016_S2352_3018_18_30039_0 crossref_primary_10_1097_QAI_0000000000003518 crossref_primary_10_1007_s11262_019_01721_8 crossref_primary_10_1186_s13059_025_03484_y crossref_primary_10_12688_f1000research_15029_1 crossref_primary_10_1016_j_micinf_2020_05_019 crossref_primary_10_3390_biom15030432 crossref_primary_10_3389_fimmu_2021_687296 crossref_primary_10_1186_s13058_020_01373_9 crossref_primary_10_1002_iid3_70138 crossref_primary_10_1016_j_domaniend_2019_106404 crossref_primary_10_1016_S2055_6640_20_30046_7 crossref_primary_10_1371_journal_ppat_1006806 crossref_primary_10_1101_gr_241372_118 crossref_primary_10_3389_fmicb_2022_912908 crossref_primary_10_3389_fimmu_2021_634832 crossref_primary_10_1097_QAD_0000000000002279 crossref_primary_10_1177_026119291704500406 crossref_primary_10_1016_j_cyto_2019_154839 crossref_primary_10_3390_molecules25204829 |
Cites_doi | 10.1021/acschembio.5b00542 10.1097/QAD.0b013e3283489d1f 10.1128/AAC.46.4.982-990.2002 10.1126/science.278.5342.1447 10.1038/382833a0 10.1006/viro.1999.0011 10.1128/JVI.01763-08 10.1097/QAD.0b013e32831cf595 10.1128/jvi.69.7.4228-4236.1995 10.1128/JVI.00056-12 10.1038/gt.2009.112 10.1172/JCI44539 10.1038/417095a 10.1128/jvi.69.9.5743-5753.1995 10.1182/blood-2010-12-327106 10.1016/j.chom.2014.11.001 10.1128/JVI.02165-06 10.1084/jem.192.10.1501 10.1016/j.virol.2014.01.020 10.1128/JVI.00728-14 10.7326/0003-4819-113-6-438 10.1126/science.1195271 10.1128/JVI.05327-11 10.1016/j.cell.2016.06.039 10.1086/315128 10.1126/science.1143767 10.1007/s11904-016-0296-x 10.1073/pnas.1111573109 10.1089/aid.2010.0161 10.1182/blood-2010-09-309591 10.1042/CS20160112 10.1016/j.cytogfr.2012.05.006 10.1089/aid.2015.0226 10.1016/j.celrep.2015.08.055 10.1093/emboj/16.23.6996 10.1182/blood-2007-06-097907 10.1128/JVI.01531-10 10.1371/journal.ppat.1003852 10.1128/JVI.01285-15 10.1086/314660 10.1097/00002030-199607000-00005 10.1006/geno.1995.1180 10.1097/QAI.0000000000001166 10.1371/journal.pmed.0050203 10.1097/QAD.0b013e32835a9950 10.1016/j.vaccine.2009.10.095 10.1016/j.micinf.2012.12.003 10.1371/journal.pone.0118794 10.1111/j.1365-2249.2009.03976.x 10.1182/blood.V92.9.3105.421k46_3105_3114 10.1097/01.qai.0000219786.88786.d8 10.1517/14712598.3.1.15 10.1128/JVI.79.22.14169-14178.2005 10.1186/gb-2002-3-7-research0034 10.1073/pnas.1108866108 10.1128/jvi.68.9.6103-6110.1994 10.1111/j.1468-3083.2012.04592.x 10.1111/j.2517-6161.1995.tb02031.x 10.1038/382829a0 10.4049/jimmunol.0903915 10.1097/00002030-199816000-00006 10.1128/JVI.00800-08 10.1084/jem.164.6.1988 10.1128/JVI.00118-15 10.1128/jvi.68.7.4650-4655.1994 10.1097/QAD.0b013e3283377a1e 10.3390/ijms17030413 10.1097/QAD.0b013e3283367836 |
ContentType | Journal Article |
Copyright | Copyright © 2017 American Society for Microbiology. Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2017 American Society for Microbiology. – notice: Copyright © 2017 American Society for Microbiology. 2017 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1128/JVI.02051-16 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
DocumentTitleAlternate | Cytokines Elevated in HIV Elite Controllers |
EISSN | 1098-5514 |
ExternalDocumentID | PMC5331794 28053103 10_1128_JVI_02051_16 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: R01 GM117901 – fundername: NIAID NIH HHS grantid: P30 AI027763 – fundername: NIAID NIH HHS grantid: R01 AI150449 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-034989 – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: P30 AI027763 – fundername: HHS | National Institutes of Health (NIH) grantid: UL1-TR000454 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-031834 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-034993 – fundername: HHS | National Institutes of Health (NIH) grantid: UL1-TR000004 – fundername: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) grantid: R24 AI067039 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-042590 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-035004 – fundername: HHS | National Institutes of Health (NIH) grantid: U01-AI-034994 |
GroupedDBID | --- -~X 0R~ 18M 29L 2WC 39C 4.4 53G 5GY 5RE 5VS 85S AAFWJ AAGFI AAYXX ABPPZ ACGFO ACNCT ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 N9A O9- OK1 P2P RHI RNS RPM RSF TR2 UPT W2D W8F WH7 WOQ YQT ~02 ~KM CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c346t-fd7464409432d37aeba3ade3ee7e4ca59d1303ab67b108fd65d6b9abcb7c34ff3 |
ISSN | 0022-538X 1098-5514 |
IngestDate | Thu Aug 21 18:24:53 EDT 2025 Thu Jul 10 17:33:13 EDT 2025 Thu Apr 03 07:06:40 EDT 2025 Tue Jul 01 01:02:48 EDT 2025 Thu Apr 24 22:56:15 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | restriction factor chemokine receptors cytokines HIV elite control |
Language | English |
License | Copyright © 2017 American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c346t-fd7464409432d37aeba3ade3ee7e4ca59d1303ab67b108fd65d6b9abcb7c34ff3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Jacobs ES, Keating SM, Abdel-Mohsen M, Gibb SL, Heitman JW, Inglis HC, Martin JN, Zhang J, Kaidarova Z, Deng X, Wu S, Anastos K, Crystal H, Villacres MC, Young M, Greenblatt RM, Landay AL, Gange SJ, Deeks SG, Golub ET, Pillai SK, Norris PJ, the Women's Interagency HIV Study. 2017. Cytokines elevated in HIV elite controllers reduce HIV replication in vitro and modulate HIV restriction factor expression. J Virol 91:e02051-16. https://doi.org/10.1128/JVI.02051-16. E.S.J. and S.M.K. contributed equally to this article. |
ORCID | 0000-0003-0526-2088 |
PMID | 28053103 |
PQID | 1855786491 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5331794 proquest_miscellaneous_1855786491 pubmed_primary_28053103 crossref_primary_10_1128_JVI_02051_16 crossref_citationtrail_10_1128_JVI_02051_16 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-03-15 |
PublicationDateYYYYMMDD | 2017-03-15 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Journal of virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 2017 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_64_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_62_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_68_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_66_2 e_1_3_2_60_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_56_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_65_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_63_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_67_2 e_1_3_2_61_2 Benjamini Y (e_1_3_2_69_2) 1995; 57 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_59_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_55_2 e_1_3_2_2_2 |
References_xml | – ident: e_1_3_2_55_2 doi: 10.1021/acschembio.5b00542 – ident: e_1_3_2_11_2 doi: 10.1097/QAD.0b013e3283489d1f – ident: e_1_3_2_56_2 doi: 10.1128/AAC.46.4.982-990.2002 – ident: e_1_3_2_22_2 doi: 10.1126/science.278.5342.1447 – ident: e_1_3_2_35_2 doi: 10.1038/382833a0 – ident: e_1_3_2_52_2 doi: 10.1006/viro.1999.0011 – ident: e_1_3_2_15_2 doi: 10.1128/JVI.01763-08 – ident: e_1_3_2_49_2 doi: 10.1097/QAD.0b013e32831cf595 – ident: e_1_3_2_18_2 doi: 10.1128/jvi.69.7.4228-4236.1995 – ident: e_1_3_2_23_2 doi: 10.1128/JVI.00056-12 – ident: e_1_3_2_48_2 doi: 10.1038/gt.2009.112 – ident: e_1_3_2_24_2 doi: 10.1172/JCI44539 – ident: e_1_3_2_59_2 doi: 10.1038/417095a – ident: e_1_3_2_17_2 doi: 10.1128/jvi.69.9.5743-5753.1995 – ident: e_1_3_2_25_2 doi: 10.1182/blood-2010-12-327106 – ident: e_1_3_2_62_2 doi: 10.1016/j.chom.2014.11.001 – ident: e_1_3_2_19_2 doi: 10.1128/JVI.02165-06 – ident: e_1_3_2_33_2 doi: 10.1084/jem.192.10.1501 – ident: e_1_3_2_66_2 doi: 10.1016/j.virol.2014.01.020 – ident: e_1_3_2_3_2 doi: 10.1128/JVI.00728-14 – ident: e_1_3_2_4_2 doi: 10.7326/0003-4819-113-6-438 – ident: e_1_3_2_28_2 doi: 10.1126/science.1195271 – ident: e_1_3_2_27_2 doi: 10.1128/JVI.05327-11 – ident: e_1_3_2_60_2 doi: 10.1016/j.cell.2016.06.039 – ident: e_1_3_2_21_2 doi: 10.1086/315128 – ident: e_1_3_2_30_2 doi: 10.1126/science.1143767 – ident: e_1_3_2_13_2 doi: 10.1007/s11904-016-0296-x – ident: e_1_3_2_39_2 doi: 10.1073/pnas.1111573109 – ident: e_1_3_2_42_2 doi: 10.1089/aid.2010.0161 – ident: e_1_3_2_12_2 doi: 10.1182/blood-2010-09-309591 – ident: e_1_3_2_31_2 doi: 10.1042/CS20160112 – ident: e_1_3_2_40_2 doi: 10.1016/j.cytogfr.2012.05.006 – ident: e_1_3_2_43_2 doi: 10.1089/aid.2015.0226 – ident: e_1_3_2_63_2 doi: 10.1016/j.celrep.2015.08.055 – ident: e_1_3_2_58_2 doi: 10.1093/emboj/16.23.6996 – ident: e_1_3_2_51_2 doi: 10.1182/blood-2007-06-097907 – ident: e_1_3_2_61_2 doi: 10.1128/JVI.01531-10 – ident: e_1_3_2_36_2 doi: 10.1371/journal.ppat.1003852 – ident: e_1_3_2_54_2 doi: 10.1128/JVI.01285-15 – ident: e_1_3_2_7_2 doi: 10.1086/314660 – ident: e_1_3_2_8_2 doi: 10.1097/00002030-199607000-00005 – ident: e_1_3_2_57_2 doi: 10.1006/geno.1995.1180 – ident: e_1_3_2_67_2 doi: 10.1097/QAI.0000000000001166 – ident: e_1_3_2_9_2 doi: 10.1371/journal.pmed.0050203 – ident: e_1_3_2_32_2 doi: 10.1097/QAD.0b013e32835a9950 – ident: e_1_3_2_47_2 doi: 10.1016/j.vaccine.2009.10.095 – ident: e_1_3_2_64_2 doi: 10.1016/j.micinf.2012.12.003 – ident: e_1_3_2_65_2 doi: 10.1371/journal.pone.0118794 – ident: e_1_3_2_50_2 doi: 10.1111/j.1365-2249.2009.03976.x – ident: e_1_3_2_14_2 doi: 10.1182/blood.V92.9.3105.421k46_3105_3114 – ident: e_1_3_2_29_2 doi: 10.1097/01.qai.0000219786.88786.d8 – ident: e_1_3_2_46_2 doi: 10.1517/14712598.3.1.15 – ident: e_1_3_2_37_2 doi: 10.1128/JVI.79.22.14169-14178.2005 – ident: e_1_3_2_68_2 doi: 10.1186/gb-2002-3-7-research0034 – ident: e_1_3_2_26_2 doi: 10.1073/pnas.1108866108 – ident: e_1_3_2_5_2 doi: 10.1128/jvi.68.9.6103-6110.1994 – ident: e_1_3_2_45_2 doi: 10.1111/j.1468-3083.2012.04592.x – volume: 57 start-page: 289 year: 1995 ident: e_1_3_2_69_2 article-title: Controlling the false discovery rate: a practical and powerful approach to multiple testing publication-title: J R Stat Soc B doi: 10.1111/j.2517-6161.1995.tb02031.x – ident: e_1_3_2_34_2 doi: 10.1038/382829a0 – ident: e_1_3_2_41_2 doi: 10.4049/jimmunol.0903915 – ident: e_1_3_2_10_2 doi: 10.1097/00002030-199816000-00006 – ident: e_1_3_2_20_2 doi: 10.1128/JVI.00800-08 – ident: e_1_3_2_38_2 doi: 10.1084/jem.164.6.1988 – ident: e_1_3_2_44_2 doi: 10.1128/JVI.00118-15 – ident: e_1_3_2_6_2 doi: 10.1128/jvi.68.7.4650-4655.1994 – ident: e_1_3_2_16_2 doi: 10.1097/QAD.0b013e3283377a1e – ident: e_1_3_2_53_2 doi: 10.3390/ijms17030413 – ident: e_1_3_2_2_2 doi: 10.1097/QAD.0b013e3283367836 |
SSID | ssj0014464 |
Score | 2.3833795 |
Snippet | A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4
+
T cell counts and control viral replication in the absence of antiretroviral... A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4 T cell counts and control viral replication in the absence of antiretroviral... A subset of HIV-infected individuals termed elite controllers (ECs) maintain CD4+ T cell counts and control viral replication in the absence of antiretroviral... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
SubjectTerms | Adult Antigens, Differentiation - biosynthesis CD4-Positive T-Lymphocytes - virology Cytokines - metabolism Female Gene Expression Regulation HIV - immunology HIV - physiology HIV Infections - immunology HIV Long-Term Survivors Humans Membrane Proteins - biosynthesis Middle Aged Pathogenesis and Immunity Plasma - chemistry Receptors, HIV - biosynthesis Virus Replication - drug effects |
Title | Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28053103 https://www.proquest.com/docview/1855786491 https://pubmed.ncbi.nlm.nih.gov/PMC5331794 |
Volume | 91 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbx2AvY9_LvtBgewruEsu27MdSEtrQdrAmJW9GsmQS6tmjdQftX787Sf5Il0K3F2MkRQm-X0535_vdEfLFjyXnecC9MMu0F0hfeLEYSy-Kc84k9noIkZx8fBIdLILZMlx2aUWGXVLL3exmK6_kf6QKYyBXZMn-g2TbTWEA7kG-cAUJw_VeMt6_rqtzzFsfTgr9W6DxiKWrwKObILUY6XyYh14gSfcH1mjVZhKM7iZUB_pheLaGRTbholLYzatZhS09bCfxqenKg3WRbdpseYdNi6S5fph-BvpWWsID8qROO_UuatdM5XSl14XogrJ7UunCO65WLjQEd-KnY2AJ0_Bc2uw0zEZ1nAkXtYCTEFPgwp6ixTqmaK3Zc2jLmNPOtpeXQ2G0Xen7SGSYnR3ugu0b2r7X-a3a2iff0-ni6CidT5bzh-SRD06F38R23DsncIxNDkLzKxqahB9_6--9acD85ZXcTq7tWSvzZ-SpEwnds5h5Th7o8gV5bBuPXr8kNy1yaIMcui4piJ0a5NAecqhFjpnsIYceltQghwJyaIMct6pFDrXIoR1yXpHFdDLfP_BcFw4vY0FUe7ni8GAwDMB8xbjQUjChNNOa6yATYaLQDBIy4nI8inMVhSqSiZCZ5LBBnrPXZKesSv2WUMZiMRIJ5gmoIM5G8Blwl5QUicwVY8mADJtHm2auRD12SilS46r6cQqCSI0g0nE0IF_b1b9saZY71n1upJSC7sQXYqLU1dVlCrYqHFhRkIwH5I2VWruTH-PxNGIDwjfk2S7AuuybM-V6ZeqzgweFx9y7e3zve_Kk-3d8IDv1xZX-CFZuLT8ZcP4BOm6sMw |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cytokines+Elevated+in+HIV+Elite+Controllers+Reduce+HIV+Replication+In+Vitro+and+Modulate+HIV+Restriction+Factor+Expression&rft.jtitle=Journal+of+virology&rft.au=Jacobs%2C+Evan+S&rft.au=Keating%2C+Sheila+M&rft.au=Abdel-Mohsen%2C+Mohamed&rft.au=Gibb%2C+Stuart+L&rft.date=2017-03-15&rft.issn=1098-5514&rft.eissn=1098-5514&rft.volume=91&rft.issue=6&rft_id=info:doi/10.1128%2FJVI.02051-16&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |